These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37735592)

  • 21. Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination.
    Taus E; Hofmann C; Ibarrondo FJ; Gong LS; Hausner MA; Fulcher JA; Krogstad P; Kitchen SG; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
    Front Immunol; 2023; 14():1100594. PubMed ID: 36860850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination.
    Casado JL; Vizcarra P; Martín-Hondarza A; Blasco M; Grandal-Platero M; Haemmerle J; Fernández-Escribano M; Vallejo A
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
    Miyamoto S; Arashiro T; Adachi Y; Moriyama S; Kinoshita H; Kanno T; Saito S; Katano H; Iida S; Ainai A; Kotaki R; Yamada S; Kuroda Y; Yamamoto T; Ishijima K; Park ES; Inoue Y; Kaku Y; Tobiume M; Iwata-Yoshikawa N; Shiwa-Sudo N; Tokunaga K; Ozono S; Hemmi T; Ueno A; Kishida N; Watanabe S; Nojima K; Seki Y; Mizukami T; Hasegawa H; Ebihara H; Maeda K; Fukushi S; Takahashi Y; Suzuki T
    Med; 2022 Apr; 3(4):249-261.e4. PubMed ID: 35261995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
    Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
    Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality.
    Jung MK; Jeong SD; Noh JY; Kim DU; Jung S; Song JY; Jeong HW; Park SH; Shin EC
    Nat Microbiol; 2022 Jun; 7(6):909-917. PubMed ID: 35577972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
    Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
    BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omicron infection-associated T- and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals.
    Barros-Martins J; Hammerschmidt SI; Morillas Ramos G; Cossmann A; Hetzel L; Odak I; Köhler M; Stankov MV; Ritter C; Friedrichsen M; Ravens I; Schimrock A; Ristenpart J; Janssen A; Willenzon S; Bernhardt G; Lichtinghagen R; Bošnjak B; Behrens GMN; Förster R
    Front Immunol; 2023; 14():1166589. PubMed ID: 37215123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
    Ogura W; Ohtsuka K; Matsuura S; Okuyama T; Matsushima S; Yamasaki S; Miyagi H; Sekiguchi K; Ohnishi H; Watanabe T
    Viruses; 2022 May; 14(5):. PubMed ID: 35632698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid
    Mestiri S; Merhi M; Inchakalody VP; Taib N; Smatti MK; Ahmad F; Raza A; Ali FH; Hydrose S; Fernandes Q; Ansari AW; Sahir F; Al-Zaidan L; Jalis M; Ghoul M; Allahverdi N; Al Homsi MU; Uddin S; Jeremijenko AM; Nimir M; Abu-Raddad LJ; Abid FB; Zaqout A; Alfheid SR; Saqr HMH; Omrani AS; Hssain AA; Al Maslamani M; Yassine HM; Dermime S
    Front Immunol; 2023; 14():1061255. PubMed ID: 36817441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia.
    Fu JYL; Pukhari MH; Bador MK; Sam IC; Chan YF
    Viruses; 2023 Mar; 15(4):. PubMed ID: 37112825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
    Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
    Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best.
    Salinas AF; Mortari EP; Terreri S; Quintarelli C; Pulvirenti F; Di Cecca S; Guercio M; Milito C; Bonanni L; Auria S; Romaggioli L; Cusano G; Albano C; Zaffina S; Perno CF; Spadaro G; Locatelli F; Carsetti R; Quinti I
    J Clin Immunol; 2021 Nov; 41(8):1709-1722. PubMed ID: 34669144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
    Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
    J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population.
    Bednarski E; Del Rio Estrada PM; DaSilva J; Boukadida C; Zhang F; Luna-Villalobos YA; Rodríguez-Rangel X; Pitén-Isidro E; Luna-García E; Díaz Rivera D; López-Sánchez DM; Tapia-Trejo D; Soto-Nava M; Astorga-Castañeda M; Martínez-Moreno JO; Urbina-Granados GS; Jiménez-Jacinto JA; Serna Alvarado FJ; Enriquez-López YE; López-Arellano O; Reyes-Teran G; Bieniasz PD; Avila-Rios S; Hatziioannou T
    mBio; 2022 Aug; 13(4):e0084022. PubMed ID: 35735743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
    Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
    Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
    Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
    Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.